



# ESMO Preceptorship on Colorectal Cancer

## PROGRAMME

**ESMO  
PRECEPTORSHIP**

**VALENCIA SPAIN  
3-4 MAY 2024**

**Co-Chairs**

Andrés Cervantes, Spain  
Erika Martinelli, Italy

# ESMO PRECEPTORSHIP PROGRAMME COLORECTAL CANCER

Multidisciplinary management, standards of care  
and future perspectives

**Valencia, Spain**  
**3-4 May 2024**

---

## CO-CHAIRS

Andrés Cervantes, Spain  
Erika Martinelli, Italy

## SPEAKERS

Myriam Chalabi, The Netherlands  
Dimitri Dorcaratto, Spain  
Michel Ducreux, France  
Elena Élez, Spain  
Claire Gallois, France  
Carolina Martínez Ciarpaglini, Spain  
Dominik Modest, Germany

---

## LEARNING OBJECTIVES

- To learn about best clinical practice in the multidisciplinary management of colorectal cancer in the adjuvant and metastatic settings
- To understand the importance of pathology, histo- and moleculopathological prognostic factors
- To learn about sequencing of treatments, adverse events and special situations

---

## ACCREDITATION

The programme of this event has been accredited with **9 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to [esmo.org](http://esmo.org).

---

## ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



---

## ORGANISATION AND CONTACTS

ESMO Head Office  
Education Department  
Via Ginevra 4, 6900 Lugano  
Switzerland  
Email: [courses@esmo.org](mailto:courses@esmo.org)  
[www.esmo.org](http://www.esmo.org)



## Friday, 3 May 2024

<b>09:00-09:15</b> 15'	<b>Welcome and introduction</b>	<b>Andrés Cervantes, ES</b> <b>Erika Martinelli, IT</b>
<b>09:15-10:50</b> 95'	<b>SESSION 1</b> <b>Localised colon cancer – Part 1</b>	<b>Chair:</b> <b>Andrés Cervantes, ES</b>
30'	Quality and rules of a good pathology report Histo- and moleculopathological biomarkers	Carolina Martínez Ciarpaglini, ES
30'	Adjuvant treatment for colon cancer stage II and III as standard of care	Michel Ducreux, FR
20'	Neoadjuvant chemotherapy for localised colon cancer as a potential option	Claire Gallois, FR
15'	Q&A	All
10:50-11:20	Coffee break	
<b>11:20-12:30</b> 70'	<b>SESSION 2</b> <b>Localised colon cancer – Part 2</b>	<b>Chair:</b> <b>Erika Martinelli, IT</b>
30'	Neoadjuvant immunotherapy for localised colorectal cancer: Facts and future prospective	Myriam Chalabi, NL
10'	Q&A	All
30'	Participants clinical case discussion (3x10')	Faculty
12:30-13:30	Lunch	
<b>13:30-14:50</b> 80'	<b>SESSION 3</b> <b>Current first-line treatment for metastatic colorectal cancer</b>	<b>Chair:</b> <b>Andrés Cervantes, ES</b>
40'	Recommendations according to ESMO guidelines: First-line strategy and specific subtypes	Erika Martinelli, IT
10'	Q&A	All
30'	Oligometastatic colorectal cancer: What to know about it and how to treat it	Elena Élez, ES
14:50-15:20	Coffee break	
<b>15:20-17:20</b> 120'	<b>SESSION 4</b> <b>Metastatic colorectal cancer: Special clinical situations</b>	<b>Chair:</b> <b>Andrés Cervantes, ES</b>
30'	How to integrate surgery in the treatment of patients with liver-only metastatic disease	Dimitri Dorcaratto, ES
45'	Presentation of three challenging clinical cases by the expert and faculty discussion	Dominik Modest, DE
15'	Q&A	All
30'	Participants clinical case discussion (3x10')	Faculty
20:30	Dinner	

## Saturday, 4 May 2024

<b>09:00-09:40</b> 40'	<b>SESSION 5</b> <b>Localized rectal cancer</b>	<b>Chair:</b> <b>Erika Martinelli, IT</b>
30'	Standard of care of localised rectal cancer	Andrés Cervantes, ES
10'	Q&A	All
<b>09:40-11:55</b> 105'	<b>SESSION 6</b> <b>Metastatic colorectal cancer: Maintenance and further lines</b>	<b>Chair:</b> <b>Andrés Cervantes, ES</b>
20'	What to do after first-line failure?	Elena Élez, ES
20'	Treating patients with chemorefractory disease: Challenges and opportunities	Dominik Modest, DE
30'	Management of treatment-related side effects: <ul style="list-style-type: none"> <li>- GI-toxicity</li> <li>- Neuropathy</li> <li>- Skin toxicity</li> <li>- Hypertension</li> <li>- Hand-foot syndrome</li> </ul>	Michel Ducreux, FR
<b>10:50-11:20</b>	<b>Coffee break</b>	
20'	How to deal with patients with BRAF mutant, G12C mutant and HER2 amplified advanced colorectal cancer after first failure	Erika Martinelli, IT
15'	Q&A	All
<b>11:55-12:25</b> 30'	<b>SESSION 7</b> <b>Metastatic colorectal cancer: Case discussion</b>	<b>Chair:</b> <b>Andrés Cervantes, ES</b>
30'	Participants clinical case discussion (3x10')	Faculty
<b>12:25-12:35</b> 10'	<b>Conclusion and farewell</b>	<b>Andrés Cervantes, ES</b> <b>Erika Martinelli, IT</b>
<b>12:35-13:35</b>	<b>Lunch</b>	

**Note:** Each 10-minute slot for clinical case discussion includes a 5' case presentation and a 5' Q&A / panel discussion